Planforge Introduces Product Maturity Level Tracking with New Gate Management Option
13.2.2025 14:30:00 CET | Business Wire | Press release
Release 25 Also Introduces First GenAI-Powered Assistant Features and Configurable Portfolio Dashboards
Planforge today announced Planforge 25, the latest release of its industry-leading project work management software. The new version introduces the Gate Management Option (GMO), an optional module developed specifically to help track the product maturity level for development projects. With version 25, Planforge also ships their first GenAI-powered assistant features as announced late last year. The release also features more configurable portfolio dashboards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213182628/en/

Planforge 25: New Gate Management Option enables seamless product maturity tracking in development projects. (Graphic: Business Wire)
Gate Management for Development Projects
With its new Gate Management Option, Planforge builds a bridge between development processes and projects by directly integrating support for process gates into project planning. A process gate is a key decision point in a workflow where progress is evaluated to ensure criteria are met before moving to the next phase. Gates are uniquely defined on the project pipeline stage level, and can then be used in project templates and plans together with progress criteria and due dates.
Process gate criteria are based on work packages (WP) and target progress levels per WP. Therefore, the maturity level per criterion can be automatically derived based on actual WP progress. Process gate maturity levels are in turn aggregated based on criteria progress levels. Also target dates for process gates can be automatically monitored based on actual versus planned finish dates of their linked work packages.
"In the technology and automotive industries, gate management today involves a lot of manual work, as project plans are not integrated with process gates in any way," said Gerald Aquila, founder & CEO of Planforge. "With Planforge 25, we are changing the game: by directly reusing existing actual project management data for monitoring and controlling process gates we can not only save many hours of work, but also cut administrative costs significantly."
Additionally, Planforge now integrates a simple but powerful gate review process where go/no-go decisions, gate revisions, and required measures can be easily tracked in a revision-safe way. This allows for early warnings and delivers more transparency and more insightful KPIs. All gate-related information is clearly summarised in dedicated new views for gates planning and controlling, covering single and multiple projects alike.
First Assistant Features of GenAI Initiative
Planforge 25 further introduces the first assistant features of the company’s broader GenAI initiative. For instance, project managers can ask the system for suggestions for SMART (specific, measurable, achievable, realistic and time-bound) project objectives based on the current project description and additional related meta data such as linked ideas. These functions are context-sensitive, directly embedded in the main user interface (in this case, the project charter) and currently powered by OpenAI's ChatGPT.
Configurable Portfolio Dashboards
After introducing custom KPIs and configurable KPI overviews last year, Planforge 25 now also makes portfolio dashboards configurable. Just like for the KPIs view, users can now easily configure the displayed widgets via drag and drop per portfolio.
Availability
Planforge is free for up to four users. Larger teams can test the project work management software via a free 30-day trial. For more information or to be among the first to try the new Gate Management Option, please contact the Planforge sales team at info@planforge.io.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213182628/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom